# To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

> **NCT04500132** · PHASE2 · COMPLETED · sponsor: **Enzychem Lifesciences Corporation** · enrollment: 63 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** EC-18
- **DRUG:** Placebo EC-18

## Key facts

- **NCT ID:** NCT04500132
- **Lead sponsor:** Enzychem Lifesciences Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-28
- **Primary completion:** 2021-02-04
- **Final completion:** 2021-02-15
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04500132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04500132, "To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04500132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*